Current Edition

Schott Pharma

About the Company

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from pre-fillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D centre in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this, SCHOTT Pharma is committed to sustainable development for society and the environment, and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers, including the top 30 leading pharma manufacturers for injectable drugs, and generated revenue of EUR 899 million in the fiscal year 2023. Further information is available at www.schott-pharma.com

Contact Details
SCHOTT Pharmaceutical Systems
Hattenbergstrasse 10
55122 Mainz
Germany
phone  +49 (0)6131/66-1589
fax  +49 (0)6131/66-1916
www.schott.com/pharma